InMed Announces Appointment of Joshua Blacher as Chief Business Officer
On of the Seed Investor's Top Stock Picks, InMed Pharmaceuticals Inc. (TSX:IN; OTCQB: IMLFF) announced a significant hiring today, adding Joshua Blacher as Chief Business Officer.
This is a great hire as InMed adds twenty years of leadership experience in senior positions in the healthcare and capital markets sectors in the United States.
It's especially important as InMed has received conditional approval to list on the Toronto Stock Exchange (TSX).
Uplisting to the TSX will bring a whole new level of institutional investors to the fold, and Mr. Blacher will be a great choice in this role.
Read the full release below:
InMed Pharmaceuticals Inc. (TSX:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the appointment of Joshua Blacher as Chief Business Officer. In this capacity, Mr. Blacher will be focusing on raising the Company’s visibility in the broader capital markets community, especially in the United States, as well as executing strategic finance initiatives and business development.
Mr. Blacher joins InMed with twenty years of leadership experience in senior positions in the healthcare and capital markets sectors in the United States. Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (NASDAQ: TRPX) and Galmed Pharmaceuticals (NASDAQ: GLMD), where he focused on strategic finance, business development, and managing relations with the investment community. Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.
Eric A. Adams, InMed’s President and CEO, commented, “Josh brings his many years of experience in successfully helping to build a larger vision for high-growth biopharmaceutical companies, executing investor-focused awareness, and putting together strategic collaborations.” Mr. Adams continued, “Adding Josh’s unique skill set to our executive team is very timely to InMed, as we have now secured the capital and human talent to drive the Company into its next stage of strategic growth and execution of our focused business model.”
“InMed’s valuable platform technology and R&D pipeline uniquely situates the Company in the high-growth, cannabinoid-based biopharmaceutical industry,” commented Mr. Blacher. “The Company is clearly positioned at the early stages of its growth trajectory and there exists a great opportunity to capitalize on its distinct business model and drive shareholder value. I am very excited to join the InMed team and look forward to helping the Company accomplish its objectives."
About InMed:
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact:
InMed Pharmaceuticals Inc.
Chris Bogart, Investor Relations and Corporate Development
T: +1-604-669-7207
E: cbogart@inmedpharma.com
READ ORIGINAL RELEASE
Read More